Integrin-Targeted Drug Discovery Summit | Virtual | August 17-19

Memo

Invigorate Your Pipeline and Drive Translational Development as the Field of Integrins Explodes The excitement surrounding integrins has been growing over the past few years, culminating in recent clinical success, innovative biology and medicinal chemistry advancements blazing the way to tackle previously undruggable disease modalities through novel integrin targets The Integrin-Targeted Drug Discovery Summit is not just the first, but the only industry-driven event sharing pioneering advances, expert insights and exclusive updates on the field of integrin drug discovery and development - from solid tumors to autoimmune diseases, from ophthalmology to fibrosis, revealing the therapeutic windows of integrins! With the vast potential of integrins as targets, this inaugural 3-day summit will unite industry trailblazers including Pliant Therapeutics, Morphic Therapeutics and 7 Hills Pharma with academic leaders, such as pioneer Dean Sheppard, to delve into the biology and chemistry of different integrins classes, MoA and explore the best approach to regulate integrins, driving translational and clinical success. Date and Time: On Tuesday August 17, 2021 at 9:00 am (ends Thursday August 19, 2021 at 5:00 pm) Prices: Drug Developer Conference Only - Early birds available: USD 1499.00,Drug Developer Full Access - Early birds available: USD 2096.00,Academic Conference Only - Early birds available: USD 1199.00,Academic Full Access - Early birds available: USD 1646.00 URL: Tickets: https://go.evvnt.com/781967-1?pid=5569 Speakers: Dean Sheppard, Chief of Pulmonary, Critical Care, Allergy and Sleep and Director of Lung Biology Center, University of California, San Francisco, Katerina Leftheris, Vice President and Head of Chemistry, Pliant Therapeutics, Kevin Hart, Principal Scientist, Inflammation, Pfizer, Scott Turner, Vice President of Translational Sciences, Pliant Therapeutics, Rajita Pappu, Scientist, Genentech, Viral Kansara, Vice President Preclinical Development, Clearside Biomedical, Susanne Kossatz, Assistant Professor, Technical University Munich, Natalia Blanco, Principal Scientist, Morphic Therapeutics, Bruce Rogers, Chief Scientific Officer, Morphic Therapeutics, Upendra Marathi, President and Chief Executive Officer, 7 Hills Pharma, Steve Kerrigan. Chief Scientific Officer. Inthelia Therapeutics, Peter Vanderslice, Co-Founder, 7 Hills Pharma, Alan Stitt, Chief Scientific Officer, Oxurion, Rik Derynck, Professor - Departments of Cell, Tissue Biology and Anatomy, University of California San Francisco, Kairbaan Hodivala-Dilke, Deputy Director and Professor, Barts Cancer Institute, Zofia Ostrowska- Podhorodecka, Researcher, University of Toronto, Horst Kessler, Senior Fellow, Technical University Munich, Bálint Mészáros, Postdoctoral Research Fellow, European Molecular Biology Laboratory, Bernhard Wehrle- Haller, Professor, University of Geneva, Peter Kaiser, Professor of Ophthalmology, Cleveland Clinic, Koichi Yuki, Senior Associate in Cardiac Anesthesia, Boston Children’s Hospital